Skip to main content
. Author manuscript; available in PMC: 2009 Feb 2.
Published in final edited form as: Eur J Pharmacol. 2007 Oct 25;580(1-2):100–115. doi: 10.1016/j.ejphar.2007.10.038

Fig. 1.

Fig. 1

Effect of cochlear round window (RW)-administered (-)-pentazocine (50 mmol) on CAP - N1 amplitudes recorded at the six indicated stimulus intensities in the (-)-pentazocine-treated (n = 3) and control animals (n = 3), of experiment 1. At each of the three baseline (time 30, 60 and 90 min) and three post-baseline recording periods (time 120, 150 and 180 min) each point represents a mean percent change in neural amplitude relative to the grand baseline mean (±S.E.M.). Open arrow at time 60 min indicates the 1μl administration of APS(80%) / DMSO(20%), delivered to the cochlear round window membrane in all animals, prior to the final 30 min baseline recording period. Filled arrow at time 90 min indicates the 2μl post-baseline administration of (-)-pentazocine (50 mmol) dissolved in APS(80%) / DMSO(20%) (n = 3), or the APS(80%) / DMSO(20%) solution delivered alone (n = 3).